Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 323

1.

Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation.

Vitale A, Spolverato G, Burra P, De Feo TM, Belli L, Donato F, Baroni GS, Marianelli T, Picciotto A, Toniutto P, Bhoori S, Passigato N, Lucà MG, Russo FP, Cillo U, Fagiuoli S; Liver Transplantation NITp working group.

Transpl Int. 2015 Sep;28(9):1055-65. doi: 10.1111/tri.12591. Epub 2015 Apr 30.

2.

Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada.

Moshyk A, Martel MJ, Tahami Monfared AA, Goeree R.

J Med Econ. 2016;19(2):181-92. doi: 10.3111/13696998.2015.1106546. Epub 2015 Nov 11.

PMID:
26453248
3.

Management of hepatitis C infection before and after liver transplantation.

Fagiuoli S, Ravasio R, Lucà MG, Baldan A, Pecere S, Vitale A, Pasulo L.

World J Gastroenterol. 2015 Apr 21;21(15):4447-56. doi: 10.3748/wjg.v21.i15.4447. Review.

4.

Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy.

Cure S, Guerra I, Cammà C, Craxì A, Carosi G.

J Med Econ. 2015;18(9):678-90. doi: 10.3111/13696998.2015.1040024. Epub 2015 Jun 5.

PMID:
25891129
5.

Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.

Fontana RJ, Brown RS Jr, Moreno-Zamora A, Prieto M, Joshi S, Londoño MC, Herzer K, Chacko KR, Stauber RE, Knop V, Jafri SM, Castells L, Ferenci P, Torti C, Durand CM, Loiacono L, Lionetti R, Bahirwani R, Weiland O, Mubarak A, ElSharkawy AM, Stadler B, Montalbano M, Berg C, Pellicelli AM, Stenmark S, Vekeman F, Ionescu-Ittu R, Emond B, Reddy KR.

Liver Transpl. 2016 Apr;22(4):446-58. doi: 10.1002/lt.24416.

6.

Prevention of hepatitis C recurrence by bridging sofosbuvir/ribavirin from pre- to post-liver transplant: a real-life strategy.

Donato MF, Morelli C, Romagnoli R, Invernizzi F, Mazzarelli C, Iemmolo RM, Montalbano M, Lenci I, Bhoori S, Pieri G, Berardi S, Caraceni P, Martini S; ITACOPS-SOF Bridging Study Group.

Liver Int. 2017 May;37(5):678-683. doi: 10.1111/liv.13322. Epub 2016 Dec 26.

PMID:
27865034
7.

Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis.

Njei B, McCarty TR, Fortune BE, Lim JK.

Aliment Pharmacol Ther. 2016 Nov;44(10):1090-1101. doi: 10.1111/apt.13798. Epub 2016 Sep 19.

8.

Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus.

Patel N, Bichoupan K, Ku L, Yalamanchili R, Harty A, Gardenier D, Ng M, Motamed D, Khaitova V, Bach N, Chang C, Grewal P, Bansal M, Agarwal R, Liu L, Im G, Leong J, Kim-Schluger L, Odin J, Ahmad J, Friedman S, Dieterich D, Schiano T, Perumalswami P, Branch A.

World J Gastroenterol. 2016 Mar 7;22(9):2844-54. doi: 10.3748/wjg.v22.i9.2844.

9.

Treatment of patients waitlisted for liver transplant with all-oral direct-acting antivirals is a cost-effective treatment strategy in the United States.

Ahmed A, Gonzalez SA, Cholankeril G, Perumpail RB, McGinnis J, Saab S, Beckerman R, Younossi ZM.

Hepatology. 2017 Jul;66(1):46-56. doi: 10.1002/hep.29137. Epub 2017 May 27.

PMID:
28257591
10.

Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin.

Globke B, Raschzok N, Teegen EM, Pratschke J, Schott E, Eurich D.

Transpl Infect Dis. 2017 Feb;19(1). doi: 10.1111/tid.12647. Epub 2017 Jan 11.

PMID:
27943544
11.

Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany.

Stahmeyer JT, Rossol S, Liersch S, Guerra I, Krauth C.

PLoS One. 2017 Jan 3;12(1):e0169401. doi: 10.1371/journal.pone.0169401. eCollection 2017.

12.

 Sofosbuvir and daclatasvir in mono- and HIV-coinfected patients with recurrent hepatitis C after liver transplant.

Castells L, Llaneras J, Campos-Varela I, Bilbao I, Crespo M, Len O, Rodríguez-Frías F, Charco R, Salcedo T, Esteban JI, Esteban-Mur R.

Ann Hepatol. 2017 Jan-Feb 2017;16(1):86-93. doi: 10.5604/16652681.1226819.

13.

Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong.

Lo AO, Chan HL, Wong VW, Wong GL.

J Gastroenterol Hepatol. 2017 May;32(5):1071-1078. doi: 10.1111/jgh.13638.

PMID:
28449343
14.

Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection.

Younossi ZM, Park H, Saab S, Ahmed A, Dieterich D, Gordon SC.

Aliment Pharmacol Ther. 2015 Mar;41(6):544-63. doi: 10.1111/apt.13081. Epub 2015 Jan 26.

15.

Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective?

Marcellusi A, Viti R, Damele F, Cammà C, Taliani G, Mennini FS.

Clin Drug Investig. 2016 Aug;36(8):661-72. doi: 10.1007/s40261-016-0414-y.

PMID:
27234943
16.

Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States.

Saint-Laurent Thibault C, Moorjaney D, Ganz ML, Sill B, Hede S, Yuan Y, Gorsh B.

J Med Econ. 2017 Jul;20(7):692-702. doi: 10.1080/13696998.2017.1307204. Epub 2017 Apr 20.

PMID:
28294645
17.

The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection.

Linas BP, Barter DM, Morgan JR, Pho MT, Leff JA, Schackman BR, Horsburgh CR, Assoumou SA, Salomon JA, Weinstein MC, Freedberg KA, Kim AY.

Ann Intern Med. 2015 May 5;162(9):619-29. doi: 10.7326/M14-1313.

18.

Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.

Saab S, Hunt DR, Stone MA, McClune A, Tong MJ.

Liver Transpl. 2010 Jun;16(6):748-59. doi: 10.1002/lt.22072.

19.

Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation.

Dumortier J, Leroy V, Duvoux C, de Ledinghen V, Francoz C, Houssel-Debry P, Radenne S, d'Alteroche L, Fougerou-Leurent C, Canva V, di Martino V, Conti F, Kamar N, Moreno C, Lebray P, Tran A, Besch C, Diallo A, Rohel A, Rossignol E, Abergel A, Botta-Fridlund D, Coilly A, Samuel D, Duclos-Vallée JC, Pageaux GP.

Liver Transpl. 2016 Oct;22(10):1367-78. doi: 10.1002/lt.24505.

20.

Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.

Curry MP, Forns X, Chung RT, Terrault NA, Brown R Jr, Fenkel JM, Gordon F, O'Leary J, Kuo A, Schiano T, Everson G, Schiff E, Befeler A, Gane E, Saab S, McHutchison JG, Subramanian GM, Symonds WT, Denning J, McNair L, Arterburn S, Svarovskaia E, Moonka D, Afdhal N.

Gastroenterology. 2015 Jan;148(1):100-107.e1. doi: 10.1053/j.gastro.2014.09.023. Epub 2014 Sep 28.

Supplemental Content

Support Center